Claudio Festuccia

List of Publications by Year
in descending order

86	2,865	147801	214800
papers	citations	31 h-index	47 g-index

90	90	90	4421
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nucleo-cytoplasmic transport as a therapeutic target of cancer. Journal of Hematology and Oncology, 2014, 7, 85.	17.0	202
2	Antitumor Effects of Saffron-Derived Carotenoids in Prostate Cancer Cell Models. BioMed Research International, 2014, 2014, 1-12.	1.9	95
3	From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis. Tumor Biology, 2016, 37, 12743-12753.	1.8	83
4	Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clinical and Experimental Metastasis, 1998, 16, 513-528.	3.3	82
5	Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocrine-Related Cancer, 2006, 13, 197-210.	3.1	79
6	Osteoblast conditioned media contain TGF-?1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. , 1999, 81, 395-403.		78
7	Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clinical and Experimental Metastasis, 2000, 18, 163-170.	3.3	74
8	HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells. Cancer Letters, 2017, 397, 1-11.	7.2	72
9	Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. Journal of Cancer Research and Clinical Oncology, 2003, 129, 165-174.	2.5	71
10	Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1Î± functional interplay. International Journal of Oncology, 2014, 44, 2121-2131.	3.3	64
11	Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocrine-Related Cancer, 2009, 16, 401-413.	3.1	63
12	Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. European Journal of Cancer, 2006, 42, 2838-2845.	2.8	62
13	Crocetin and Crocin from Saffron in Cancer Chemotherapy and Chemoprevention. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 38-47.	1.7	60
14	Osteoblast-derived TGF-Î²1 modulates matrix degrading protease expression and activity in prostate cancer cells. International Journal of Cancer, 2000, 85, 407-415.	5.1	59
15	XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). Journal of Hematology and Oncology, 2014, 7, 46.	17.0	59
16	The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma. Journal of Hematology and Oncology, 2017, 10, 5.	17.0	56
17	Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. Oncotarget, 2016, 7, 5383-5400.	1.8	53
18	Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. International Journal of Cancer, 1996, 69, 386-393.	5.1	50

#	Article	IF	Citations
19	KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer, 2015, 15, 941.	2.6	50
20	Hormonal Therapy Promotes Hormone-Resistant Phenotype by Increasing DNMT Activity and Expression in Prostate Cancer Models. Endocrinology, 2011, 152, 4550-4561.	2.8	48
21	CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. Prostate, 2015, 75, 1227-1246.	2.3	45
22	The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumor Biology, 2017, 39, 101042831769552.	1.8	44
23	PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocrine-Related Cancer, 2013, 20, 321-337.	3.1	43
24	Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. International Journal of Oncology, 2014, 44, 285-294.	3.3	43
25	The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. Cancers, 2019, 11, 359.	3.7	42
26	Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid. European Journal of Medicinal Chemistry, 2018, 150, 930-945.	5.5	39
27	Î”5-Cholenoyl-amino acids as selective and orally available antagonists of the Ephâ€“ephrin system. European Journal of Medicinal Chemistry, 2015, 103, 312-324.	5.5	38
28	Crocetin Extracted from Saffron Shows Antitumor Effects in Models of Human Glioblastoma. International Journal of Molecular Sciences, 2020, 21, 423.	4.1	37
29	Surgical and Biologic Outcomes After Neoadjuvant Bicalutamide Treatment in Prostate Cancer. Urology, 2007, 70, 728-733.	1.0	35
30	The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Endocrine-Related Cancer, 2011, 18, 385-400.	3.1	35
31	Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1â€mediated survivin function and delaying DNA repair in prostate cancer models. Prostate, 2014, 74, 852-868.	2.3	35
32	Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. International Journal of Oncology, 2013, 42, 2116-2122.	3.3	33
33	Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate, 2008, 68, 793-801.	2.3	31
34	The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy. International Journal of Molecular Sciences, 2021, 22, 3863.	4.1	31
35	Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocrine-Related Cancer, 2007, 14, 601-611.	3.1	29
36	Akt downâ€modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate, 2008, 68, 965-974.	2.3	29

#	Article	IF	Citations
37	Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. Journal of Hematology and Oncology, 2017, 10, 161.	17.0	29
38	NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. Journal of Cancer Research and Clinical Oncology, 2019, 145, 881-893.	2.5	28
39	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. Journal of Leukocyte Biology, 2021, 109, 969-989.	3.3	28
40	UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget, 2018, 9, 24347-24363.	1.8	28
41	Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. International Journal of Oncology, 2007, 30, 193-200.	3.3	28
42	Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. International Journal of Oncology, 2011, 40, 711-20.	3.3	27
43	Tebuconazole and Econazole Act Synergistically in Mediating Mitochondrial Stress, Energy Imbalance, and Sequential Activation of Autophagy and Apoptosis in Mouse Sertoli TM4 Cells: Possible Role of AMPK/ULK1 Axis. Toxicological Sciences, 2019, 169, 209-223.	3.1	25
44	Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 393-409.	2.5	25
45	Characterization of Prostate Cancer DU145 Cells Expressing the Recombinant Androgen Receptor. Oncology Research, 2003, 14, 101-112.	1.5	24
46	Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate, 2009, 69, 1529-1537.	2.3	24
47	The possible prognostic role of histone deacetylase and transforming growth factor Î²/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study. European Journal of Histochemistry, 2017, 61, 2732.	1.5	24
48	The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. Journal of Hematology and Oncology, 2018, 11, 32.	17.0	24
49	Bombesin-Dependent Pro-MMP-9 Activation in Prostatic Cancer Cells Requires Î²1 Integrin Engagement. Experimental Cell Research, 2002, 280, 1-11.	2.6	22
50	Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models. Tumor Biology, 2016, 37, 341-351.	1.8	22
51	Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Cancer Letters, 2019, 461, 90-101.	7.2	22
52	Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate, 2010, 70, 1340-1349.	2.3	21
53	Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1031-1041.	1.7	21
54	In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate, 2007, 67, 1255-1264.	2.3	20

#	Article	IF	Citations
55	Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth. Cells, 2020, 9, 32.	4.1	19
56	Effects of Dutasteride on Prostate Carcinoma Primary Cultures: A Comparative Study With Finasteride and MK386. Journal of Urology, 2008, 180, 367-372.	0.4	18
57	Impregnation of Curcumin into a Biodegradable (Poly-lactic-co-glycolic acid, PLGA) Support, to Transfer Its Well Known In Vitro Effect to an In Vivo Prostate Cancer Model. Nutrients, 2019, 11, 2312.	4.1	18
58	Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization. Journal of Biomedical Science, 2020, 27, 90.	7.0	18
59	The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties. Frontiers in Pharmacology, 2020, 11, 552428.	3.5	17
60	Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer. Oncotarget, 2017, 8, 111225-111245.	1.8	16
61	MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. International Journal of Molecular Sciences, 2021, 22, 10671.	4.1	14
62	Can the AGE/RAGE/ERK signalling pathway and the epithelial-to-mesenchymal transition interact in the pathogenesis of chronic rhinosinusitis with nasal polyps?. European Journal of Histochemistry, 2020, 64, .	1.5	13
63	Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, inÂvitro and inÂvivo, the alveolar phenotype subtype. International Journal of Radiation Biology, 2021, 97, 943-957.	1.8	13
64	Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models. Oncotarget, 2017, 8, 29865-29886.	1.8	12
65	Evaluation of metastatic potential in prostate carcinoma: an in vivo model. International Journal of Oncology, 2004, 25, 1713-20.	3.3	12
66	The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. Cancers, 2019, 11, 1604.	3.7	11
67	Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Oncology Reports, 2007, 18, 503-11.	2.6	11
68	Targeted Molecular Therapy in Glioblastoma. Journal of Oncology, 2020, 2020, 1-3.	1.3	10
69	ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma. Cancers, 2022, 14, 289.	3.7	10
70	Synergistic Activity of Ketoconazole and Miconazole with Prochloraz in Inducing Oxidative Stress, GSH Depletion, Mitochondrial Dysfunction, and Apoptosis in Mouse Sertoli TM4 Cells. International Journal of Molecular Sciences, 2022, 23, 5429.	4.1	10
71	Her2 crosstalks with TrkA in a subset of prostate cancer cells: Rationale for a guided dual treatment. Prostate, 2009, 69, 337-345.	2.3	9
72	Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines In Vitro and In Vivo. Journal of Oncology, 2020, 2020, 1-16.	1.3	9

#	Article	IF	Citations
73	Lactobacillus sakei Pro-Bio65 Reduces TNF-Î± Expression and Upregulates GSH Content and Antioxidant Enzymatic Activities in Human Conjunctival Cells. Translational Vision Science and Technology, 2021, 10, 8.	2.2	9
74	Evaluation of metastatic potential in prostate carcinoma: An in vivo model. International Journal of Oncology, 2004, 25, 1713.	3.3	8
75	Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. Journal of Cancer Research and Clinical Oncology, 2005, 131, 243-254.	2.5	8
76	Antitumor effects of carnertinib in castration resistant prostate cancer models: A comparative study with erlotinib. Prostate, 2011, 71, 1481-1491.	2.3	8
77	Dual PI3â€‰K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling. Tumor Biology, 2018, 40, 101042831877177.	1.8	7
78	The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Is Synergistic With Radiotherapy in Models of Human Glioblastoma. Frontiers in Pharmacology, 2022, 13, 852941.	3.5	7
79	Targeting DDX3X Helicase Activity with BA103 Shows Promising Therapeutic Effects in Preclinical Glioblastoma Models. Cancers, 2021, 13, 5569.	3.7	6
80	Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. Oncology Reports, 2007, 18, 1321-7.	2.6	6
81	Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. International Journal of Oncology, 2008, 33, 381-8.	3.3	6
82	Increased matrix metalloproteinaseâ€9 secretion in shortâ€term tissue cultures of prostatic tumor cells. International Journal of Cancer, 1996, 69, 386-393.	5.1	4
83	Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma. Pharmaceuticals, 2021, 14, 1082.	3.8	4
84	Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. International Journal of Oncology, 2004, 25, 97-104.	3.3	4
85	Investigational serine/threonine kinase inhibitors against prostate cancer metastases. Expert Opinion on Investigational Drugs, 2017, 26, 25-34.	4.1	1
86	Editorial (Thematic Issue: New Drug Targets for Treatment of Recurrent/Metastatic Prostate Cancer). Current Drug Targets, 2016, 17, 254-256.	2.1	0